Epicardial Fat, Visceral Fat and Coronary Atherosclerosis

Association Between Epicardial Fat, Visceral Fat Accumulation & Cardiovascular Atherosclerosis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01344694

Enrollment

110

Registered

2011-04-29

Start date

2011-07-31

Completion date

2012-03-31

Last updated

2011-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Epicardial Fat, Visceral Fat

Keywords

Epicardial fat, Visceral fat, atherosclerosis, coronary computed tomography angiography, Carotid Doppler ultrasound

Brief summary

Detailed description

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear. Aim: Evaluate the link between epicardial fat, visceral fat, liver fat accumulation and cardiovascular diseases and carotis atherosclerosis in patients with the major cardiovascular risk factors and with or without metabolic syndrome.

Interventions

OTHERpatient with liver fat

30 patient with liver fat

OTHERpts. with excess of visceral fat

pts. with excess of visceral fat

OTHERcontrol

30 control subjects

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients referred to cardiac CT will be the source of recruitment. * patients with excess of visceral fat, * 30 patients with liver fat accumulation * 30 sex-age-matched individual (controls) will be enrolled. All patients will undergo a complete family history, personal clinical history, physical examination and blood sampling for biochemical analysis. * Informed consent will be obtained from each individual.

Exclusion criteria

* subjects with severe morbid obesity (body mass index \[BMI\] \> 40), * recent history of acute illness, * clinical history of ischemic heart disease and cerebrovascular disease, * typical chest pain, * previous coronary artery disease, * conventional coronary angiography, percutaneous interventions, coronary by pass grafting, renal failure, cancer patients, * subjects who take drugs that induces hepatic steatosis ( corticosteroids, estrogens, methotrexate, amiodarone and others)

Countries

Israel

Contacts

Primary ContactNimer Assy, MD

assy.n@ziv.health.gov.il972-46828442

Backup ContactNimer Assy